Portal de Periódicos da CAPES

The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate Cancer

2003; Lippincott Williams & Wilkins; Volume: 170; Issue: 5 Linguagem: Inglês

10.1097/01.ju.0000091640.59812.83

1527-3792

Monique M. Cherrier, Andrea L. Rose, Celestia S. Higano,

Cancer survivorship and care

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2003The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate Cancer M.M. CHERRIER, A.L. ROSE, and C. HIGANO M.M. CHERRIERM.M. CHERRIER , A.L. ROSEA.L. ROSE , and C. HIGANOC. HIGANO View All Author Informationhttps://doi.org/10.1097/01.ju.0000091640.59812.83AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Men with prostate specific antigen (PSA) only relapse of prostate cancer after primary therapy are generally fully functional and asymptomatic with a life expectancy of up to 10 or more years. These patients are often treated with androgen suppression. We evaluate the effects of androgen suppression on cognitive function. Materials and Methods: Hormone naïve patients without evidence of metastases with an increasing PSA were treated with intermittent androgen suppression consisting of 9 months of leuprolide and flutamide followed by an off treatment period determined by the increase in PSA. Cognitive function tests were administered at baseline, after 9 months of androgen suppression and after 3 months off treatment. Cognitive tests measured spatial abilities, spatial memory, verbal fluency, verbal memory and selective attention. A total of 19 patients 52 to 76 years old completed the intermittent androgen suppression study along with 15 healthy community dwelling control participants. Results: Combined androgen blockade reduced PSA and testosterone in all patients compared to baseline. Patients did not significantly change on measures of verbal and spatial memory, executive functions or language. Patients declined on a measure of spatial rotation and improved on a measure of verbal memory during treatment which continued during the off treatment period. Conclusions: Although preliminary, these findings demonstrate that 9 months of combined androgen blockade resulted in a beneficial effect on verbal memory but adversely affected a measure of spatial ability. Intermittent androgen suppression for a period of 9 months in otherwise healthy men with prostate cancer may have beneficial and adverse effects on cognition that are selective. References 1 : Cancer statistics 2001: quo vadis or whither goest thou?. CA Cancer J Clin2001; 51: 11. Google Scholar 2 : Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol1998; 160: 1398. Link, Google Scholar 3 : Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol1996; 58: 139. Google Scholar 4 : Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology1996; 48: 800. Google Scholar 5 : Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc Am Soc Clin Oncol1999; 18: 314a. Google Scholar 6 : Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology2001; 57: 127. Google Scholar 7 : Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab2002; 87: 5001. Google Scholar 8 : Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology2001; 57: 80. Google Scholar 9 : Concussion in contact sports: reliable change indices of impairment and recovery. J Clin Exp Neuropsychol1999; 21: 70. Google Scholar 10 : Sex and Cognition. Cambridge: MIT Press1999. Google Scholar 11 : Testosterone levels and spatial ability in men. Psychoneuroendocrinology1999; 24: 813. Google Scholar 12 : Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci2000; 114: 1245. Google Scholar 13 : Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril1996; 65: 1253. Google Scholar 14 : "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab1996; 81: 2545. Google Scholar 15 : Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet1993; 10: 53. Google Scholar 16 : A relationship between gonadotropins and visuospatial function. Neuropsychologia1986; 24: 563. Google Scholar 17 : The effects of intrahippocampal testosterone and flutamide on spatial localization in the Morris water maze. Brain Res2001; 897: 44. Google Scholar 18 : Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst1998; 90: 1537. Google Scholar 19 : Memory functioning at menopause: impact of age in ovariectomized women. Gynecol Obstet Invest1999; 47: 29. Google Scholar From the Departments of Psychiatry and Behavioral Sciences (MMC) and Medicine (ALR, CH), University of Washington School of Medicine, Seattle, Washington© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByGriebling T (2018) Re: Cognitive Function in Patients with Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter StudyJournal of Urology, VOL. 200, NO. 2, (222-225), Online publication date: 1-Aug-2018.Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, Dobs A, DeWeese T, Carducci M and Basaria S (2018) Lack of an Effect of High Dose Isoflavones in Men With Prostate Cancer Undergoing Androgen Deprivation TherapyJournal of Urology, VOL. 182, NO. 5, (2265-2273), Online publication date: 1-Nov-2009.Beer T, Bland L, Bussiere J, Neiss M, Wersinger E, Garzotto M, Ryan C and Janowsky J (2018) Testosterone Loss and Estradiol Administration Modify Memory in MenJournal of Urology, VOL. 175, NO. 1, (130-135), Online publication date: 1-Jan-2006.Joly F, Alibhai S, Galica J, Park A, Yi Q, Wagner L and Tannock I (2018) Impact of Androgen Deprivation Therapy on Physical and Cognitive Function, as Well as Quality of Life of Patients With Nonmetastatic Prostate CancerJournal of Urology, VOL. 176, NO. 6, (2443-2447), Online publication date: 1-Dec-2006. Volume 170Issue 5November 2003Page: 1808-1811 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostatic neoplasmscognitionandrogen antagoniststestosteroneflutamideMetricsAuthor Information M.M. CHERRIER Supported by Grant K01AG00858 from the National Institute on Aging. More articles by this author A.L. ROSE Supported by Grant K12CA76930 from the National Institutes of Health. More articles by this author C. HIGANO Financial interest and/or other relationship with Cell Therapeutics Inc., Myriad Pharm, Atrix Lab, Takeda Pharmaceuticals, Novartis, Dendreon, TAP Pharmaceuticals, Lilly, Cell Genesys, Abbott, NW Biotherapeutics and Abgenix. More articles by this author Expand All Advertisement PDF DownloadLoading ...